Survey: Patients expect medical errors, look to technology for fixes

female doctor, young male patient - 51.36 Kb
The bad news: Almost three-quarters of Americans worry about medical mistakes. The good news: Some 68 percent trust technology to allay their fears.

Wolters Kluwer Health returned those numbers after surveying 1,000 adults on medical mistakes and finding that 30 percent have experienced a healthcare error either personally or through a family member.

Errors cited by respondents include being given the wrong drugs or the right drugs but at a wrong dosage, receiving an incorrect diagnosis and being put on an inappropriate treatment plan.

Nearly half, 45 percent, said they had been incorrectly billed.

More than one-third of respondents, 35 percent, cited “miscommunication among hospital staff” as the top explanation for medical mistakes. Also named were doctors and nurses being in a hurry (26 percent), staff being fatigued (14 percent) and hospitals experiencing staffing shortages (12 percent).

Further findings from the survey:
  • 84 percent of respondents have taken some type of action to reduce risk when it comes to their own healthcare. The most common action is doing their own research to validate a doctor’s diagnosis or treatment plan (66 percent).
  • 19 percent have delayed a procedure for a day when the doctor may be more focused or rested.
  • 18 percent have asked a doctor/nurse to wash their hands.

Philadelphia-based publisher and software vendor Wolters Kluwer Health said it completed survey interviews in July and weighted data to align the sample group’s demographics with U.S. Census Bureau data on the population as a whole. The firm has posted the survey report’s executive summary.
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.